What Will Happen to Keryx Biopharmaceuticals (KERX) Next? The Stock Just Increased A Lot

September 17, 2017 - By Winifred Garcia

Investors sentiment increased to 1.22 in 2016 Q4. Its up 0.15, from 1.07 in 2016Q3. It increased, as 9 investors sold Keryx Biopharmaceuticals shares while 32 reduced holdings. 19 funds opened positions while 31 raised stakes. 65.62 million shares or 1.53% more from 64.63 million shares in 2016Q3 were reported.
Tiaa Cref Invest Limited Com holds 0% or 227,286 shares in its portfolio. The Pennsylvania-based Nationwide Fund has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Montana-based Da Davidson And has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Royal Fincl Bank Of Canada holds 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX) for 56,031 shares. Citadel Advisors Ltd Limited Liability Company holds 47,309 shares. Tower Research Llc (Trc) reported 0% stake. Iridian Asset Mgmt Ltd Com Ct reported 228,570 shares. Wells Fargo Com Mn reported 60,939 shares. Fin Architects invested in 282 shares. Ridgeworth Management Ltd Co holds 0% or 55,878 shares in its portfolio. Point72 Asia (Hong Kong) invested in 0% or 100 shares. One Trading Lp, a Illinois-based fund reported 268,727 shares. Principal Gp Inc has invested 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX). Shufro Rose And Limited invested in 0.05% or 72,700 shares. Commonwealth Equity Svcs reported 0% stake.

Since April 5, 2017, it had 0 buys, and 6 sales for $59,425 activity. Holmes Scott A had sold 1,441 shares worth $8,603 on Monday, May 1. Another trade for 642 shares valued at $3,724 was sold by Adams Brian. 1,441 shares valued at $8,603 were sold by Neylan John F. on Monday, May 1. 911 shares were sold by Madison Greg, worth $5,284.

The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) is a huge mover today! The stock increased 5.89% or $0.4 on September 15, reaching $7.19. About 3.03M shares traded or 197.06% up from the average. Keryx Biopharmaceuticals (NASDAQ:KERX) has risen 13.56% since September 17, 2016 and is uptrending. It has underperformed by 3.14% the S&P500.
The move comes after 5 months positive chart setup for the $853.81M company. It was reported on Sep, 17 by Barchart.com. We have $7.77 PT which if reached, will make NASDAQ:KERX worth $68.30M more.

Wall Street await Keryx Biopharmaceuticals (NASDAQ:KERX) to release earnings on November, 8. Analysts forecast earnings per share of $-0.17, up exactly $0.22 or 56.41 % from 2014’s $-0.39 EPS. After posting $-0.21 EPS for the previous quarter, Keryx Biopharmaceuticals’s analysts now forecast -19.05 % EPS growth.

Keryx Biopharmaceuticals (NASDAQ:KERX) Ratings Coverage

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals had 35 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. The company was maintained on Thursday, July 27 by Cowen & Co. Maxim Group upgraded Keryx Biopharmaceuticals (NASDAQ:KERX) on Wednesday, November 9 to “Buy” rating. The rating was maintained by Morgan Stanley on Tuesday, July 25 with “Equal-Weight”. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Market Perform” rating by Raymond James on Wednesday, September 9. The rating was initiated by Morgan Stanley on Thursday, August 13 with “Underweight”. The company was downgraded on Tuesday, August 2 by Brean Capital. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Neutral” rating by JP Morgan on Friday, February 26. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Equal-Weight” rating by Morgan Stanley on Monday, October 5. The rating was maintained by Maxim Group with “Buy” on Thursday, July 27.

More notable recent Keryx Biopharmaceuticals (NASDAQ:KERX) news were published by: Globenewswire.com which released: “Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare …” on September 05, 2017, also Seekingalpha.com with their article: “Keryx Biopharmaceuticals’ (KERX) CEO Greg Madison on Q1 2017 Results …” published on May 04, 2017, Nasdaq.com published: “Keryx Biopharmaceuticals (KERX) Up 5% Since Earnings Report: Can It Continue?” on June 09, 2017. More interesting news about Keryx Biopharmaceuticals (NASDAQ:KERX) were released by: Globenewswire.com and their article: “Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and …” published on July 27, 2017 as well as Seekingalpha.com‘s news article titled: “Keryx Biopharmaceuticals: Catalyst In Upcoming FDA Decision” with publication date: August 09, 2017.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical firm focused on the development of medicines for people with renal disease. The company has market cap of $853.81 million. The Firm is engaged in the manufacture, development and commercialization of products for use in treating human diseases. It currently has negative earnings. The Company’s marketed product, Auryxia , which is an orally available, absorbable, iron medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.